Interleukin 17 (IL-17) is a proinflammatory cytokine that contributes to host protection against a range of infectious pathogens by inducing neutrophil recruitment and secretion of inflammatory mediators^[@R1]^. The IL-17 cytokine family comprises six related proteins: IL-17A (also called IL-17), IL-17B, IL-17C, IL-17D, IL-17E (also called IL-25) and IL-17F. The best-studied members, IL-17A and IL-17F, share the highest homology and are coordinately secreted by multiple subsets of immune cells as homodimers or IL-17A--IL-17F heterodimers^[@R2]^.

The description of new sources and mechanisms responsible for IL-17 production may have critical relevance in the understanding of IL-17-mediated immune responses during infection and autoimmunity. In addition to its impact in bacterial and fungal infections, emerging data implicate IL-17 in the control of selected parasitic pathogens^[@R3]--[@R5]^. Consistent with this theme, recent work has suggested an important role for IL-17 in resolution of infection with the protozoan parasites, *Trypanosoma cruzi* (*T. cruzi*) and *Trypanosoma congolense*^[@R6]--[@R8]^. Indeed, prior work from our group indicates that IL-17 exerts its protective function following exposure of mice to *T. cruzi*, in part, by recruiting suppressive IL-10--producing neutrophils that modulate interferon-γ (IFN-γ) production and thereby limit tissue damage^[@R9]^. In the absence of this IL-17 dependent response, infected animals exhibit markedly increased liver pathology and overwhelming wasting disease.

During the course of *T. cruzi* infection, we observed that IL-17 was produced by multiple cell populations including: NKT cells and γδ, CD4^+^ (T~H~17) and CD8^+^ (T~C~17) T cells^[@R9]^. Each of these hematopoietic-derived cell subsets has previously been identified as an IL-17 producing population^[@R1],[@R10]^. Interestingly, we also observed a predominant cell population, present during peak parasitemia, lacking relevant lineage markers for each of these lineages. In this study, we have identified this new cellular source of IL-17 and determined the signals required to promote IL-17 production by such cells in response to *T. cruzi* infection. Our combined data provide the first demonstration that B lineage cells secrete IL-17 in response to challenge with an infectious pathogen. B cell-intrinsic IL-17A production was triggered via a novel signaling cascade in response to a *T. cruzi*-derived extracellular enzyme and was required for efficient parasite control.

RESULTS {#S1}
=======

*T. cruzi* infection triggers generation of IL-17^+^ B cells {#S2}
------------------------------------------------------------

To identify the cell populations responsible for IL-17 production during *T. cruzi* infection, we characterized the phenotype of IL-17A--producing cells in mice infected with 10,000 trypomastigotes of *T. cruzi* (Y strain)^[@R11]^. Surprisingly, most IL-17A-producing cells in the spleen at day 10 post-infection lacked CD3 expression. Instead, these cells consistently expressed the prototypical B lineage cell surface protein, CD19, as well as lower amounts of the B cell antigen, B220 ([Fig. 1a](#F1){ref-type="fig"}). Although CD4^+^ IL-17A-producing (T~H~17) cells were generated during *T. cruzi* infection, IL-17A^+^ B220^+^ cells significantly outnumbered T~H~17 cells at days 10 and 19 post infection ([Fig. 1b](#F1){ref-type="fig"}) and no significant increase in CD8^+^ IL-17-producing cells occurred at either time-point. Analyzing additional B cell markers, we determined that a proportion of CD19^+^ IL-17A^+^ cells expressed the plasmablast or plasma cell marker, CD138, but lacked the germinal center markers, GL7 and PNA ([Fig. 1c](#F1){ref-type="fig"} and data not shown). These observations suggested that plasma cell-committed B cells, but not germinal center B cells, are able to produce IL-17. In agreement, immunofluorescence analysis of the spleen ([Fig. 1d](#F1){ref-type="fig"}) identified an IgM^hi^ IL-17^+^ cell population outside the (less strongly staining IgM^lo^) splenic follicle and proximal to the central arteriole (T cell zone), a finding consistent with the abundant extrafollicular plasmablast response previously characterized during *T. cruzi* infection^[@R12]^.

To verify these results, we quantified IL-17A mRNA in total splenocytes and in sorted CD19^+^ B220^+^ B cells versus CD19^−^ B220^−^ non-B cells derived from infected mice. Abundant IL-17A mRNA was present upon stimulation of CD19^+^ B220^+^ B cells ([Fig. 1e](#F1){ref-type="fig"}). In contrast, transcripts were undetectable in B cells isolated from non-infected mice (not shown). B220^−^ non-B cells from infected mice also exhibited abundant IL-17A mRNA expression, suggesting that a subset of non-B cells produced somewhat higher amounts of IL-17 transcripts on a per cell basis compared with B cells. Next, we directly measured IL-17A in culture supernatants from purified, splenic-derived, CD19^+^B220^+^ cells from infected versus uninfected control animals. In the absence of any additional stimulus, B cells from infected animals spontaneously secreted IL-17A and cytokine production was further enhanced using PMA plus ionomycin stimulation ([Fig. 1f](#F1){ref-type="fig"}). No IL-17A production was detected in either stimulated or resting B cells cultures established using uninfected animals.

To confirm the B cell origin of the CD19^+^ B220^+^ IL-17^+^ cells induced during *T. cruzi* infection, we studied this population in µMT mice, animals that lack mature B cells. B220^+^ IL-17^+^ cells were undetectable in *T. cruzi* infected µMT mice ([Fig. 1g,h](#F1){ref-type="fig"}). Development of this population was restored, however, in recipients of adoptively transferred mature B cells ([Fig. 1g,h](#F1){ref-type="fig"}). IL-17^+^ cells induced in B cell-reconstituted, infected µMT mice showed a surface phenotype indistinguishable from that observed in infected wild-type mice (B220^dim^CD19^+^CD138^+^GL7^−^PNA^−^ IL-17^+^ cells; [Fig. 1g](#F1){ref-type="fig"}).

Taken together, these results provide the first demonstration that B cells are able to secrete the proinflammatory cytokine IL-17A in response to challenge with an infectious pathogen. Further, these data indicate that, during *T. cruzi* infection, IL-17 producing B cells are a major source of this cytokine, outnumbering T~H~17 cells.

B cell IL-17A production promotes *T. cruzi* parasite control {#S3}
-------------------------------------------------------------

To test the physiologic relevance of IL-17 production by B cells during *T. cruzi* infection, we adoptively transferred wild-type or IL-17A-deficient B cells into µMT recipients and infected these animals with *T. cruzi*. While equivalent B cell reconstitution was achieved in all recipient animals ([Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}), control µMT mice, and µMT recipients of IL-17A-deficient B cells, exhibited increased parasitemia compared with recipients of wild-type B cells ([Fig. 2a](#F2){ref-type="fig"}) and, ultimately, this lead to accelerated mortality ([Fig. 2b](#F2){ref-type="fig"}). Lack of B cell IL-17A production was associated with elevated IFN-γ and tumor necrosis factor (TNF) concentrations ([Fig. 2c,d](#F2){ref-type="fig"}). These differences correlated with increased tissue damage as manifest by transaminitis ([Fig. 2e](#F2){ref-type="fig"}). Thus, B cells are the major producers of IL-17A during acute *T. cruzi* infection and B cell-intrinsic IL-17A production is critical for the protective response to this pathogen.

B cells utilize alternative IL-17 triggering signals {#S4}
----------------------------------------------------

We next determined the signals leading to B cell IL-17 production during *T. cruzi* infection. The cytokines, IL-23 and IL-6, strongly promote IL-17 production by γδ and CD4^+^ T cells^[@R1],[@R10]^. Surprisingly, infected IL-23R-deficient or IL-6-deficient mice showed no difference in the number of B220^+^ IL-17^+^ cells in comparison to infected wild-type mice, implying that these signals were not required for B cell IL-17A production ([Supplementary Fig. 2a](#SD1){ref-type="supplementary-material"}). Further, B-T cell cooperation through the CD40 pathway^[@R13]^ was also not required as similar numbers of IL-17-producing B220^+^ cells were detected in infected CD40-deficient versus control mice ([Supplementary Fig. 2a](#SD1){ref-type="supplementary-material"}).

Microbial products that trigger C-type lectin- and Toll-like-receptors (TLR) promote IL-17 production by innate cells^[@R10]^. Moreover, TLR ligands are critically involved in B cell activation and differentiation^[@R14],[@R15]^ and mediate the immune recognition of *T. cruzi*^[@R16]^. Thus, we analyzed whether direct triggering of TLRs or the B cell antigen receptor (BCR) induced IL-17 production by purified B cells *in vitro*. No significant IL-17 production was detected in cultures supernatants of normal splenic B cells stimulated with various doses of Zymosan (a dectin-1 and TLR2 ligand), lipopolysaccharide (LPS, TLR4 ligand), CpG (TLR9 ligand), anti-IgM or CpG plus anti-IgM ([Supplementary Fig. 2b](#SD1){ref-type="supplementary-material"}), indicating that TLR, BCR or dual cross-linking were insufficient to induce potent IL-17 production. Consistent with these data, we observed no defect in B220^+^ IL-17^+^ generation in infected µMT mice that were recipients of adoptively transferred mature B cells lacking a key adaptor protein required for TLR signaling, MyD88 (data not shown).

*T. cruzi* triggers IL-17^+^ B cell generation *in vitro* {#S5}
---------------------------------------------------------

As *T. cruzi* is a complex microorganism that initiates a cascade of direct and indirect lineage-specific activation events *in vivo* ^[@R16]^, we determined whether *in vitro* parasite exposure was sufficient to initiate IL-17 production by purified B cells. Indeed, live *T. cruzi* trypomastigotes rapidly induced parasite dose-dependent IL-17A production by follicular mature (FM) B cells ([Fig. 3a](#F3){ref-type="fig"} and data not shown). Similarly, antigen from total homogenates of *T. cruzi* trypomastigotes induced detectable, albeit less, IL-17A secretion by total splenic B cells ([Fig. 3a](#F3){ref-type="fig"}). Of note, the purity (\>90--95%) and phenotype of flow cytometry-sorted B cells was confirmed in this and all subsequent experiments.

Interestingly, using highly purified splenic B cell subsets, mature (marginal zone or FM), but not immature (transitional) B cells, secreted both IL-17A and IL-17F following exposure to live parasites ([Fig. 3b,c](#F3){ref-type="fig"}). Lack of cytokine expression by transitional B cells was not due to reduced cell viability (data not shown). Importantly, neither total spleen cells from RAG2-deficient mice nor wild-type non-B or purified T cells produced IL-17A after *T. cruzi* stimulation *in vitro* ([Supplementary Fig. 2c--d](#SD1){ref-type="supplementary-material"}), indicating that a contaminating non-B or -T cell population or residual T cells could not account for IL-17 production in response to parasite encounter.

Additionally, we evaluated the participation of key B cell surface proteins in triggering IL-17 production *in vitro*. Consistent with our *in vivo* data, cytokine production was not altered by loss of the co-stimulatory receptor, CD40, or the TLR signaling adaptor, MyD88. We also observed no impact on IL-17 production by restricting BCR specificity to recognition of a non-parasite associated antigen (hen-egg lysozyme; [Supplementary Fig. 2e](#SD1){ref-type="supplementary-material"}). Thus, direct exposure of B cells to *T. cruzi* trypomastigotes was sufficient to initiate B cell IL-17 production.

*T. cruzi* trans-sialidase drives IL-17^+^ B cell formation {#S6}
-----------------------------------------------------------

Polyclonal B cell activation is a hallmark of acute *T. cruzi* infection^[@R17],[@R18]^, implying that a range of *T. cruzi* surface antigens might be capable of triggering an IL17 program. We noted that IL-17A--producing B cells were most abundant at peak parasitemia, a time point coinciding with a strong polyclonal B cell activation. Therefore, we investigated whether candidate polyclonal activators expressed on the surface of *T. cruzi* might be sufficient to trigger B cell IL-17 production. We focused our efforts on *T. cruzi* trans-sialidase, an abundant, parasite cell surface, GPI-anchored enzyme required for parasite invasion^[@R19]^ and previously shown to exhibit potent T cell-independent B cell mitogenic activity^[@R20]^. Strikingly, recombinant, enzymatically active, trans-sialidase efficiently triggered, dose-dependent, IL-17A production by murine B cells ([Fig. 3d](#F3){ref-type="fig"}).

*T. cruzi* trans-sialidase is comprised of an N-terminal catalytic domain and a long C-terminal domain containing of multiple 12-amino-acid (DSSAHSTPSTPA) tandem repeats, also known as the Shed-Acute-Phase-Antigen (SAPA)^[@R21]^. Trans-sialidase activity is critical for *T. cruzi* pathogenesis^[@R22],[@R23]^ and a natural point-mutation (Tyr342His), that abrogates enzymatic activity while retaining N-terminal lectin-like activity, prevents many immunological alterations induced by trans-sialidase *in vivo* ^[@R23]^. In contrast, strong antigenicity^[@R21]^ and B cell mitogenic activity^[@R20]^ is present in the SAPA motifs of the C-terminal moiety. We therefore analyzed IL-17A secretion following B cell stimulation with recombinant, Tyr342His mutant trans-sialidase. While mutant trans-sialidase was still able to trigger some IL-17A production, cytokine production was significantly lower than with active trans-sialidase ([Fig. 3d](#F3){ref-type="fig"}); indicating that enzymatic activity is required for a robust response and that either the SAPA repeats or residual N-terminal lectin activity may partially mediate cytokine production. To further assess the role for SAPA repeats, we utilized a neutralizing mAb directed against the catalytic site of trans-sialidase^[@R22],[@R24]^, a reagent that blocks both enzymatic function and residual lectin activity. Anti-trans-sialidase, but not control, mAb treatment abrogated trans-sialidase- or trypomastigote-induced IL-17 production ([Fig. 3e](#F3){ref-type="fig"}), implicating trans-sialidase as the sole *T. cruzi* molecule required in this process.

Glycoconjugate remodeling promotes B cell IL-17 secretion {#S7}
---------------------------------------------------------

Trans-sialidase exhibits a unique enzymatic activity, first described in trypanosomatids, that promotes transfer of α(2,3)-linked sialic acid from host glycoconjugates to acceptor proteins on the parasite surface or to recipient host molecules^[@R25]^. In the absence of suitable acceptors, trans-sialidase also displays neuraminidase activity leading to hydrolysis of α(2,3)-linked sialyl residues^[@R26]^. We evaluated the role for these alternative enzymatic activities in IL-17 secretion by B cells in our experimental system. We first tested whether IL-17A production was induced after hydrolysis of sialyl residues using neuraminidases derived from candidate bacteria species including *Vibrio cholerae* (specific for α(2,3)-linked sialyl residues) and *Clostridium perfringens* (able to hydrolyze α(2,3); α(2,6) and α(2,8)-linked sialyl residues). No IL-17A was detected upon B cell stimulation with several doses of bacterial neuraminidases, suggesting that desialylation of B cell-surface molecules was not sufficient to trigger of IL-17 production ([Fig. 3f](#F3){ref-type="fig"} and data not shown).

Because trans-sialidase is able to sialylate lymphocyte membrane proteins *in vivo*^[@R26]^ and protein specific sialylation is associated with alterations in immune function^[@R27],[@R28]^, we tested whether trans-sialidase-catalyzed modification of host B cell surface molecules might promote IL-17 production. For this, B cells were cultured with BSA under serum-free conditions to avoid presence of soluble donor or acceptors of sialyl residues. Production of IL-17 in the presence of trans-sialidase or parasites was detected only when the sialyl donor, α(2,3)-sialyl-lactose, but not the control sugar, α(2,6)-sialyl-lactose, was present, linking sialylation of B cells with IL-17A production ([Fig. 3g](#F3){ref-type="fig"}).

To better mimic physiological conditions, where serum glycoproteins act not only as donors but also as suitable residue acceptors, we carried out experiments where lactose was added as a sialyl residue acceptor. Under these conditions, the production of IL-17 was markedly enhanced ([Fig. 3g](#F3){ref-type="fig"}). Together, these data supported the notion that the simple acquisition of sialyl residues on the B cell triggers modest IL-17 secretion whereas the more complete surface glycoconjugate remodeling that occurs in the presence of sialyl donor or acceptor molecules promotes a vigorous IL-17 response program.

CD45 is required for generation of IL-17^+^ B cells {#S8}
---------------------------------------------------

Trans-sialidase has been reported to catalyze sialylation of host acceptor molecules including the protein-tyrosine phosphatase, CD45, on the surface of T lymphocytes^[@R25]^. While never directly tested, these events have been postulated to promote immune abnormalities induced by this enzyme. As an initial screen for the potential role for CD45 in the B cell IL-17 program, we utilized a CD45-specific inhibitor (N-(9,10-Dioxo-9,10-dihydro-phenanthren-2-yl)-2,2-dimethyl-propionamide). We observed a significant reduction in IL-17A and IL-17F production when sorted B cells were co-incubated with *T. cruzi* trypomastigotes and increasing doses of inhibitor ([Fig. 4a](#F4){ref-type="fig"}, [Supplementary Fig. 3a](#SD1){ref-type="supplementary-material"} and data not shown).

Next we assessed the genetic requirement for CD45 in the *in vitro* IL-17 effector response using B cells isolated from CD45-deficient mice. In contrast to wild-type B cells, CD45-deficient B cells failed to produce IL-17A or -17F in response to parasite exposure ([Fig. 4a](#F4){ref-type="fig"} and [Supplementary Fig. 3a](#SD1){ref-type="supplementary-material"}). Further, in contrast to wild-type counterparts, B cells from CD45-deficient mice adoptively transferred into recipient µMT mice, were unable to restore the B220^+^ IL-17^+^ population generated following *T. cruzi* infection ([Fig. 4b--c](#F4){ref-type="fig"}).

Galectins are sugar-binding proteins that participate in multiple immune responses^[@R29]^ and galectin-1 and -3 binding to CD45 can modulate T lymphocyte survival^[@R30]^. These lectins are produced by B cells in response to *T. cruzi* infection^[@R31],[@R32]^ and might recognize sialylation changes induced by trans-sialidase. Parasite induced IL-17, however, was unimpaired by B cell-intrinsic loss of Galectin-1 or-3 ruling out a role for these lectins in these events ([Fig. 4d](#F4){ref-type="fig"}).

IL-17^+^ B cell production requires Src and Btk signals {#S9}
-------------------------------------------------------

We next addressed the potential intracellular signaling pathways leading to B cell IL-17 production. Consistent with the key role for CD45 in regulating Src family kinase activity, Src inhibition markedly attenuated IL-17 production in trypomastigote-stimulated B cells ([Fig. 4e](#F4){ref-type="fig"} and [Supplementary Fig. 3b](#SD1){ref-type="supplementary-material"}). As previous work implicated the non-receptor tyrosine kinase, Btk, in trans-sialidase--mediated B cell mitogenic activity^[@R33]^, we analyzed whether Btk or Tec kinases and other downstream Btk effectors, including PKCβ and NF-κB^[@R34],\ [@R35]^ were required. Addition of specific, covalent Btk-Tec inhibitors (AVL-292 or CNX-652) strongly reduced IL-17A, and abrogated IL-17F, production ([Fig. 4f](#F4){ref-type="fig"} and [Supplementary Fig. 3c](#SD1){ref-type="supplementary-material"}). In agreement, little or no IL-17 was detected following activation of B cells derived from Btk-deficient mice and IL-17 cytokine production was abrogated in parasite-stimulated Btk-Tec doubly deficient B cells ([Fig. 4f](#F4){ref-type="fig"} and [Supplementary Fig. 3c](#SD1){ref-type="supplementary-material"}). Of note, deletion of Tec kinases or addition of various inhibitors had no appreciable impact on B cell survival in these assays (data not shown). Consistent with these findings, CD19^+^ IL-17^+^ B cells were markedly decreased in Btk-deficient mice following *in vivo* T. cruzi infection ([Fig. 4g](#F4){ref-type="fig"})

Interestingly, IL-17 production by B cells cultured with *T. cruzi* was not affected by the deficiency of a key Btk effector, PKCβ ([Fig. 4h](#F4){ref-type="fig"}). PKCβ signaling is essential for BCR-driven NF-kB activation. Consistent with the lack of requirement for PKCβ, pharmacologic inhibition of NF-kB also had no impact on IL-17 production ([Supplementary Fig. 4a](#SD1){ref-type="supplementary-material"}). Together, these results demonstrate that *T. cruzi* triggers a CD45--Src-family--Btk-Tec dependent signaling cascade that initiates B cell-specific IL-17 production.

B cells do not utilize the 'canonical' IL-17 program {#S10}
----------------------------------------------------

The transcription factor, RORγt, is essential for differentiation of naïve T cells into T~H~17 cells and subsequent expression of IL-17^[@R2],[@R36]^. Studies, to date, have also demonstrated a requirement RORγt in all IL-17 producing lineages including 'innate' IL-17 cells^[@R10]^. Based on these data, we evaluated of the requirement for RORγt in B cell IL-17 production. Surprisingly, when stimulated using either *T. cruzi* trypomastigotes or trans-sialidase, RORγt-deficient and wild-type B cells produced similar concentrations of IL-17A and IL-17F ([Fig. 5a](#F5){ref-type="fig"}). Consistent with the requirement for trans-sialidase in these events, IL-17 production was blocked in both populations by addition of the anti-trans-sialidase mAb.

The related nuclear receptor, RORα, can synergize with RORγt to promote T~H~17 lineage development. We stimulated purified wild-type B cells with trypomastigotes in the presence, or absence, of the RORα- and RORγt-specific inhibitor, SR1001, and observed no effect on B cell IL-17 production ([Fig. 5b](#F5){ref-type="fig"}). The ligand-dependent transcription factor, aryl hydrocarbon receptor (AHR), also promotes T~H~17 lineage development and production of IL17 and the T~H~17 cytokine, IL-22^[@R37]^. Purified, trypomastigote-stimulated, AHR-deficient and wild-type B cells generated similar amounts of IL-17A ([Fig. 5b](#F5){ref-type="fig"}). In concert with these *in vitro* data, *T. cruzi* infection lead to equivalent numbers of CD19^+^IL-17^+^ B cells in RORγt-deficient, AHR-deficient and wild-type mice ([Fig. 5c](#F5){ref-type="fig"}).

As an alternative means to address the role for RORγt, we performed immunofluorescence studies using spleens obtained from non-infected vs. *T. cruzi* infected RORγt reporter mice. While all T cells expressed the RFP reporter^[@R38]^ due to transient expression of RORγt during thymocyte development^[@R39]^, we failed to identify IgM^+^RFP^+^ B cells following infection ([Fig. 5d](#F5){ref-type="fig"}). Consistent with these findings and the intact CD19^+^IL17^+^ response in *T. cruzi* infected IL-23R-deficient and IL-6-deficient mice ([Supplementary Fig. 2a](#SD1){ref-type="supplementary-material"}), IL-17 production in B cells stimulated *in vitro* was unaffected by B intrinsic loss of IL-6 or combined absence of both the IL-21- and IL-23 receptors ([Supplementary Fig. 4b](#SD1){ref-type="supplementary-material"}).

Together, these results demonstrate that exposure to *T. cruzi* trans-sialidase initiates a RORγt-, RORα-and AHR-independent, B cell transcriptional program; a program that bypasses the canonical signals utilized by T~H~17 and innate IL-17 cells.

*T. cruzi* promotes human B cell IL-17 production {#S11}
-------------------------------------------------

To determine whether this signaling cascade was operational in primary human B cells in response to *T. cruzi*, we carried out *in vitro* studies using purified tonsillar CD19^+^ B cells. Cells were cultured in media alone, or in association with recombinant human IL-10 or the B cell cytokine, BAFF, to facilitate cell survival, and concurrently stimulated with *T. cruzi* trypomastigotes. Human IL-17 production was consistently triggered in response to parasite exposure ([Fig. 6](#F6){ref-type="fig"}). In contrast to murine B cells, IL-17F was slightly more abundant than IL-17A. IL-17F was detectable in cultures supernatants stimulated with parasites alone, and potentiated by addition of IL-10 or BAFF. IL-17A was identified only in parasite-stimulated, IL-10 or BAFF-supplemented, cultures. Importantly, consistent with our findings using murine B cells, IL-17 production was abrogated by addition of an anti-trans-sialidase mAb. Further, addition of CD45- or Btk-specific inhibitors significantly reduced IL-17 production. Cell viability was improved in cultures containing IL-10 or BAFF and the addition of inhibitors had no appreciable impact on survival (data not shown). Thus, *T. cruzi* trans-sialidase drives IL-17 production in human B cells via an analogous CD45--Btk-dependent signaling program.

DISCUSSION {#S12}
==========

Our combined findings identify B cells as a major source for rapid, innate-like IL-17 production in response to *T. cruzi* infection. IL-17^+^ B cells were present at the time of peak parasitemia and outnumbered T~H~17 cells throughout the course of infection. Notably, acute *T. cruzi* infection is associated with polyclonal B cell activation and, congruent with this response, IL-17^+^ B cells exhibited a plasmablast phenotype (CD19^+^B220^dim^GL7^−^CD138^+^). Thus, our data suggest that, in addition to antibody secretion, IL-17 production may comprise an additional key effector function for plasma cells in this infection. Consistent with this idea, B cell-intrinsic, IL-17A production was required for efficient control of parasitemia and regulation of parasite inflammatory responses. Strikingly, B cell IL-17 production in response to *T. cruzi* trypomastigotes occurred via a novel pathway triggered by parasite-derived trans-sialidase. Our data support a model whereby this enzyme directly modifies the B cell surface protein, CD45 (or indirectly impacts CD45 activity via modification of another B cell surface protein), thereby triggering Src- and Btk-Tec kinase-family dependent intracellular signaling. These signals, ultimately, drive abundant IL-17 production via a ROR-γt--AHR-independent transcriptional program. Importantly, this signaling program operated in both murine and human primary B cells.

Genetic deletion or pharmacological blockade of CD45, respectively, abrogated B cell IL-17 production. Thus, specific alterations in CD45 structure or localization unique to trans-sialidase-modified B cells appear to be directly or indirectly required to initiate IL-17 production. The receptor-like protein tyrosine phosphatase, CD45, is expressed on all nucleated hematopoietic cells and comprises one of the most abundant cell surface glycoproteins. CD45 plays an essential role in B and T cell antigen receptor signal transduction and also modulates integrin and cytokine receptors signals by controlling the relative threshold of sensitivity to external stimuli^[@R40]^. Notably, the functional activity of CD45 is precisely regulated via the structural features of its extracellular domain. Distinct lymphoid populations express specific CD45 isoforms due to alternative splicing of exons within the extracellular domain. Developing and activated lymphocytes also differ with respect to extent of extracellular domain glycosylation as well as site-specific O- and N-glycan sialylation, and such micro-heterogenous changes impact cell survival and activation^[@R41]^. Interestingly, in contrast to B cells, exposure of primary T cells to *T. cruzi* trypomastigotes failed to trigger IL-17 production despite previous evidence for trans-sialidase-mediated modification of CD45 on T cells. Similarly, trypomastigote-stimulated myeloid cells and neutrophils also did not generate IL-17. Thus, trans-sialylation of CD45 (or of CD45 interacting molecules) on B cells likely functions in a novel manner to initiate signaling. Both the enzymatic and residual N-terminal lectin-activity of trans-sialidase, but not the repetitive C-terminal SAPA motifs, were required for maximal B cell IL-17 production *in vivo*. These findings suggest that trans-sialidase triggers a unique manner of CD45 compartmentalization or oligomerization that initiates the IL-17 transcriptional program. This program operated independently of key candidate B cell surface receptors including CD40 and MyD88-dependent innate receptors. CD45 oligomerization may help to explain why these events did not require antigen-specific BCR recognition. However, whether this program requires the scaffold function of an intact BCR, integrins or other B cell surface receptor(s) remains to be determined. Interestingly, unlike mature B cells, purified transitional B cells failed to respond to *T. cruzi* trypomastigotes (or trans-sialidase), implying that a B cell stage-specific CD45 isoform or a mature transcriptional development program^[@R42]^ is essential for these events.

CD45 modulates signal transduction thresholds as either a positive or negative regulator of Src family kinases, with its dominant activity dependent upon its precise localization. Using inhibitors and genetic models we demonstrated a requirement for both Src- and Btk-Tec kinases in this pathway B cells. Based upon our previous work^[@R43]^, we hypothesize that trans-sialylation of CD45 initiates Src kinase-dependent trans-phosphorylation of the activation loop tyrosine within Btk-Tec kinases. Activated Btk is capable of directly trans-phosphorylating a range of signaling effectors including PLC-γ2, adaptor proteins and transcription factors^[@R34],[@R44]^. Surprisingly, IL-17 production did not require the Btk-dependent, essential BCR downstream effectors PKCβ and NF-κB. We are currently utilizing high sensitivity mass-spectroscopy to identify proximal signaling intermediates modified in response to trans-sialidase exposure in primary B cells.

The orphan nuclear receptor and transcription factors, RORγt and RORα, play an essential role in the IL-17 program in T~H~17, T~C~17 and innate IL-17 producing cells including γδ T cells and *i*NKT, NK, and LTi-like cells^[@R2],[@R10],[@R36]^. In naïve T cells, initial and sustained expression of RORγt is coordinately controlled via signaling inputs from key environmental cytokines (IL-1, IL-6, TGF-β, IL-21 and IL-23) that mediate STAT3 activation and the interplay of additional transcription factors. Additional effectors, including AHR, also function to sustain IL-17 production in RORγt-expressing cells. Thus, one of the most surprising findings in this study was that generation of IL-17^+^ B cells occurred independently of RORγt, RORα and AHR expression or activity; and, similarly, that the B cell IL-17 program was unimpeded by lack of IL-6, IL-21 or IL-23R. Notably, while neutrophils are also capable of producing IL-17^[@R45]^, it remains unknown whether these cells require RORγt, raising the possibility that other innate cells might utilize RORγt-independent programs for IL-17 production. Our findings set the stage for assays designed to identify proximal effectors and nuclear factors required for B cell IL-17 transcription; work that may provide new insight into the biology of this cytokine family.

In summary, our findings demonstrate that B cells can be driven to rapidly secrete IL-17A and IL-17F in response to challenge with an infectious pathogen and that IL-17^+^ B cells comprise a major source for this cytokine during *T. cruzi* infection. Our data leave several important open questions. Most importantly, these observations suggest that generation of IL-17^+^ B cells may be an unappreciated feature of the innate immune response required for pathogen control in other disease settings. In this context, several bacterial species, including *Streptococcus pneumoniae, Campylobacter jejuni* and *Pasteurella multocida*, also express trans-sialidases^[@R46]--[@R49]^. Further, both B lineage cells and IL-17 are strongly implicated in a range of autoimmune disorders. Indeed, low-level, chronic *T. cruzi* infection leads to life-threatening chronic inflammatory sequelae that comprise a major disease burden in parasite endemic regions^[@R50]^. Thus, it will be important to determine the role(s) for IL-17^+^ B cells in this clinically important setting as well as in candidate autoimmune disorders.

ONLINE METHODS {#S13}
==============

Mice {#S14}
----

Control C57BL6, BALBc, µMT, IgHEL (Hen egg lysozyme-specific immunoglobulin transgenic), *Il23r^−/−^, Il21r^−/−^ Il23r^−/−^, Il6^−/−^, Myd88^−/−^, Cd40^−/−^, Rag2^−/−^, Btk^−/−^, Btk^−/−^ Tec^−/−^, Pkcb^−/−^, Ahr^−/−^*, RORγt-GFP homo- and heterozygotes, and RORγt-cre×ROSA-RFP mice were maintained in the specific pathogen--free barrier facilities at Seattle Children\'s Research Institute. Animal studies were carried out with the approval of Seattle Children\'s Research Institute Institutional Animal Care and Use Committee. Spleens from control C57BL6, *Cd45^−/−^* and *Il17a^−/−^* animals were kindly donated by A. Weiss (UCSF) and D. Artis (U Penn), respectively.

For experiments performed in Argentina, C57BL6 mice were originally obtained from School of Veterinary, La Plata National University (La Plata, Argentina) and were housed in School of Chemical Sciences animal facility where all experiments were performed in compliance with the Institutional Review Board and Ethical Committee of the School of Chemical Sciences, National University of Cordoba. B6.Cg-Lgals3^tm1Poi^ Lgals1^tm1Rob^J (*Gal-1^−/−^Gal-3^−/−^*) mice (Jackson Laboratory) were bred at the UNSAM animal facilities in accordance with the Institutional Review Board and Ethical Committees.

Infections with *T. cruzi* {#S15}
--------------------------

*T. cruzi* parasites (Y-Br strain, kindly provided by K. Norris, U. Pittsburgh) were cultured in NIH 3T3 fibroblasts and harvested as previously described^[@R51]^. 6--8 week-old mice were infected by intraperitoneal injection of 1×10^4^ Tp diluted in Glucose 2%-PBS solution^[@R51]^. Tp dose was selected to maximize level of parasitemia without impacting survival^[@R11]^. Uninfected normal littermates were injected with PBS and processed in parallel. Level of whole blood parasitemia was measured by counting viable trypomastigotes in a Neubauer counting chamber^[@R18],\ [@R31]^.

Adoptive B cell transfer experiments {#S16}
------------------------------------

Purified splenic B cells (\>95% purity) from C57BL6, *Il17a^−/−^, Cd45^−/−^, Il23r^−/−^, Il6^−/−^, Myd88^−/−^* or *Cd40^−/−^* mice were obtained by CD43^+^ cell depletion (Miltenyi Biotec) or sorting by flow cytometry (as below) and transferred into μMT recipients (3.5--5×10^7^ B cells per recipient). 5 days post-transfer, recipient mice were infected with 1×10^4^ trypomastigotes via intraperitoneal injection.

Flow cytometry and cell sorting {#S17}
-------------------------------

Single cell suspensions were obtained by dissociating spleens with frosted glass slides. Erythrocytes were lysed with ammonium chloride potassium phosphate (ACK) buffer. Viable leukocytes numbers was determined by trypan blue exclusion using a Neubauer counting chamber. Single cell suspensions were incubated with fluorescently labeled antibodies for 20 min at 4 °C. The following antibodies were used for flow cytometry: anti-B220-PECy7 (RA3-6B2); anti-CD19-Alexa Fluor 700 or PECy7 (1D3); anti-GL-7-Alexa Fluor 647 (GL7); anti-CD4-PeCy5 (RM-5), anti-CD8-PerCPCy5.5 (53--6.7), anti-CD24-APC (M169) ); anti-CD21 (7G6) and anti-CD138-Biotin (281-2) followed by Streptavidin-APC-Cy7; and anti-IL-17-PE (eBio17B7) from (eBioscience). Anti-PNA-FITC was purchased from Vector (USA). Data were collected on a LSR II or FACs-CANTO flow cytometer (BD Biosciences) and analyzed using FlowJo software (TreeStar).

For intracellular cytokine staining, cells were stimulated with 50 ng/ml PMA, 500 ng/ml ionomycin and GolgiStop (BD Biosciences) for 5 h. After surface-staining, cells were fixed and permeabilized with CytofixCytoperm (BD Biosciences) according manufacturer's instructions.

For cell sorting, B cells were enriched using CD43 MicroBeads (Miltenyi Biotec) prior to surface staining and sorting using a FACSAria sorter with Diva software (BD Biosciences). Sort gates were defined based on B220, CD19, CD21, CD23 and CD4 expression: FM B cells (CD21^int^CD24^int^ CD23^+^), MZ B cells (CD21^hi^CD24^hi^CD23^−^) and T1 B cells (CD21^lo^CD24^hi^CD23^+^). Sort purities were \>97%.

Tonsillar human B cells {#S18}
-----------------------

Tonsils (discarded surgical specimens) were obtained in accordance with the guidelines of the Institutional Review Board of Seattle Children's Hospital and Seattle Children's Reseach Insitute. Mononuclear cells were isolated by mechanical disruption of tonsil tissue followed by Ficoll-Hypaque gradient centrifugation. Highly pure B cells (\>98% purity) were obtained by depletion of magnetically labeled non-B cells (B Cell Isolation Kit II; Miltenyi Biotec).

B cell cultures {#S19}
---------------

Sorted splenic B cells (CD19^+^ B220^+^) or B cell sub-populations (FM, MZ and T1) from uninfected or *T. cruzi* infected (day 10 post infection) mice were cultured *in vitro* with varying doses of trypomastigotes or with media, F(ab\')~2~ anti-IgM (10 µgml; Jackson ImmunoResearch Laboratories), TLR agonists (LPS 10 µg/ml (Sigma); CpG 2 µg/ml;; Zymozan 50 µg/ml (Invivogen)) or *T. cruzi* trans-sialidase (active or Tyr342His inactive forms; 5 µg/ml^[@R52]^; or *T. cruzi* antigen. In separate experiments, B cells were cultured with trypomastigotes in the presence of: anti-trans-sialidase-neutralizing mAb^[@R22]^ or a IgG2a isotype control; CD45 Inhibitor: N-(9,10-Dioxo-9,10-dihydro-phenanthren-2-yl)-2,2-dimethyl-propionamide (Calbiotech); Src inhibitor: PP2, 4-Amino-5-(4-chlorophenyl)-7-(*t*-butyl)pyrazolo\[3,4-d\]pyrimidine (EMB Millipore); Btk inhibitors AVL-292 and CNX-652 (kindly provided by Avila Therapeutics); NFκB inhibitor BAY 11-7082; RORγt and RORα inhibitor SR1001^[@R53]^ kindly provided by T Burris (Scripps) or DMSO as control.

For human B cell stimulation, B cells were incubated in 96-well plates (10^6^ cells per well in 200 µl RPMI 1640 supplemented with 10% FBS) for 72 h with 10 ng/ml soluble BAFF or IL-10 in the presence of trypomastigotes with different concentrations of AVL-292 (50 nM), DMSO (control), anti-trans-sialidase-neutralizing mAb or CD45 Inhibitor (0.25 nM). After 72 h, supernatants were analyzed for IL-17 production by ELISA.

Sialylation and desialylation assays {#S20}
------------------------------------

Sorted B220^+^ splenocytes from uninfected mice were cultured with different doses of bacterial *Vibrio cholerae* (SIGMA N6514) and *Clostridium perfringens* neuraminidases (SIGMA N2876) for 72 h. In separate experiments, B cells were cultured with 30 mM of α-(2,3)sialyllactose (α-2,3-SL) and α-(2,6)sialyllactose (α-2,6-SL) in medium containing FBS or 2% BSA with or without acceptor lactose for 72 h. IL-17A production in the supernatants was determined by ELISA.

Cytokine quantification {#S21}
-----------------------

Cytokine concentrations in supernatants from *in vitro* cultures and in sera were determined by ELISA using paired antibodies for human or murine IL-17A or IL-17F (eBiosciences) and murine IFN-γ and TNF (eBiosciences) according to manufacturer's instructions.

Transaminase quantification {#S22}
---------------------------

Plasma aspartate aminotransferase (AST) and alanine aminotransferase (ALT) activity was measured using commercial kits according to manufacturer's instructions.

Reverse transcription of mRNA and quantification by real time PCR {#S23}
-----------------------------------------------------------------

Sorted splenic B cells (CD19^+^ B220^+^) and non-B cells (CD19^−^ B220^−^) from uninfected and *T. cruzi* infected (10 d post infection) mice were stimulated for 5 h with 50 ng/ml PMA, 500 ng/ml ionomycin. Cells were incubated with TRIzol™ (Life Technologies) and RNA was extracted according to the manufacturer\'s instructions and stored at −70 °C. RNA was reverse transcribed using Moloney murine leukemia virus reverse transcriptase (Invitrogen, USA) at 42 °C for 60 min. One microgram of RNA was used to generate initial cDNA species. Real-time PCR reactions for mouse IL-17A and HPRT were performed using the following primers pairs and probes IL-17A (Mm00439618_m1) and HPRT (Mm00446968_m1) (Applied Biosystems). HPRT was used as standard to normalize cDNA loading^[@R54]^.

Immunofluorescence {#S24}
------------------

Spleens from uninfected and *T. cruzi* infected (10 d post infection) wild-type and RORγt-Cre-ROSA RFP mice were fixed in 4% paraformaldehyde and embedded in OCT prior to sectioning. 8 µm sections were rehydrated in staining buffer (PBS, 1% goat serum, 1% BSA, and 0.1% Tween-20), pre-incubated with anti-mouse CD16CD32 (Fc Block™, BD Biosciences), then stained with antibodies including: anti-IgM-FITC (Southern Biotech), anti-IL-17A-PE (eBioscience) anti-CD3-Alexa647 (Invitrogen) and anti-B220-FITC (BD Biosciences). Images were acquired using a DM6000B microscope, DFL300 FX camera, and Application Suite Advanced Fluorescence software (all from Leica).

Statistical analysis {#S25}
--------------------

Statistical significance of comparisons of mean values was assessed by a two-tailed Student's *t*-test or nonparametric Mann-Whitney *U*-test and, in the case of multiple experimental group comparisons, by one-way ANOVA with Bonferroni correction using GraphPad software.
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![B cells from *T. cruzi* infected mice produce IL-17\
(**a**) Representative flow cytometry plots showing IL-17A expression in B220^+^ cells in the spleen of wild-type (WT) and µMT mice infected with *T. cruzi* at 10 days (d) post-infection. (**b**) Number of IL-17A-expressing splenic CD4^+^, CD8^+^ and B220^+^ cells in uninfected (UI), or 10 and 19 d *T. cruzi*-infected mice (WT or µMT). Each symbol denotes a single animal and the line represents the mean value in each group (6--9 animals per group). Data are representative of 4 independent experiments. (**c**) IL-17A expression (at 10 d) in total splenocytes from *T. cruzi*-infected WT mice (left) and in gated CD19^+^ cells expressing the plasma cell marker, CD138, or the GC B cell marker, GL7 (right). Data are representative of 3 experiments. (**d**) Immunofluorescence staining of splenic sections from UI and *T. cruzi* infected (10 d) mice showing IL-17A and IgM expression (magenta and cyan, respectively, left; and merged images, right). Arrow indicates IL-17^+^IgM^+^ cells. Dashed lines surround less strongly staining (e.g. IgM^lo^) B cell follicles (\*). Data are representative of 3 experiments. (**e**) IL-17A mRNA expression in total, sorted B220^+^ and B220^−^ splenocytes from infected mice cultured in media alone or with PMA and ionomycin (PMA+Iono). HPRT was used for normalization (10 d, 3 replicates per condition). (**f**) IL-17A production by B220^+^ splenocytes from UI or infected (Inf) mice cultured with medium or PMA+Iono for 72 h (10 d, 3 replicates per condition). Data (e--f) are representative of 2 experiments. (**g**) IL-17A^+^ B220^+^ cells in *T. cruzi*-infected µMT or B-cell reconstituted µMT (µMT + B cells) mice (10 d). Lower panel shows IL-17A expression predominantly within the B220^+^CD138^+^ gate. Data are representative of 3 experiments. (**h**) Number of IL-17^+^ B220^+^ cells within the spleen of UI or Inf WT, µMT or B cell reconstituted µMT mice (10 d; 6--7 mice per condition). Data are representative of 3 experiments. All error bars denote s.e.m. \*, P ≤ 0.05 \*\*, P ≤ 0.005 (calculated by Mann-Whitney *U*-test).](nihms445334f1){#F1}

![B cell IL-17A production is required for *T. cruzi* infection control\
Control WT, µMT, or µMT mice reconstituted with WT or *Il17a^−/−^* B cells, were infected with *T. cruzi* and evaluated for: **(a)** Parasitemia (left panel: kinetic; right panels: day 10 and 15); **(b)** Survival based on Kaplan-Meier survival curve; **(c)** Serum IFNγ and TNF concentrations; and, **(e)** plasma aspartate aminotransferase (AST) and alanine aminotransferase (ALT) activity. Surviving animals were sacrificed at 20 d and **(d)** IFN-γ and TNF production by unstimulated splenocytes was quantified (72 hour *in vitro* culture). Each symbol denotes a single animal and the line represents the mean value in each group. All error bars denote s.e.m. \*, P ≤ 0.05 \*\*, P ≤ 0.005 (calculated by Mann-Whitney *U*-test). Results shown are from 2 independent experiments with 3--4 animals per group in each experiment.](nihms445334f2){#F2}

![Exposure to *T. cruzi* trypomastigotes or purified trans-sialidase is sufficient to trigger B cell IL-17 production\
(**a,d--g**) IL-17A secretion by B220^+^CD19^+^ cells or (**b--c**) IL-17A and IL-17F production by follicular (FM), marginal zone (MZ) and transitional 1 (T1) B cell subsets purified from spleens of UI WT mice and stimulated for 72 h with: **(a)** various doses of live *T. cruzi* trypomastigotes (Tryp) or *T. cruzi* antigen (Ag); or (**b--g**) 1 × 10^6^ Tryp or different doses of active vs. inactive trans-sialidase (Tsial) with or without a Tsial-neutralizing mAb (α-Tsial) or IgG2a isotype control. **(f)** B220^+^CD19^+^ cells from UI WT mice were cultured with Tryp, Tsial or different doses of bacterial *V. cholerae* and *C. perfringens* neuramidases (NA). **(g)** B220^+^CD19^+^ cells from WT mice were cultured with Tryp or Tsial for 72 h in medium containing FBS or 2% BSA with alpha(2,3)-sialyllactose (α-2,3-SL) and alpha(2,6)-sialyllactose (α-2,6-SL) or in identical media lacking acceptor lactose. All error bars denote s.e.m. \*, P ≤ 0.05 \*\*, P ≤ 0.005 (calculated by Mann-Whitney *U*-test). Results are representative of 3 independent experiments with 2 replicates per condition. ND: None detectable.](nihms445334f3){#F3}

![CD45 and Btk are required for B cell IL-17 production in response to *T. cruzi* trypomastigotes or purified trans-sialidase\
(**a**) IL-17A production in follicular B cells from WT mice in response to *T. cruzi* Tryp and treated with or without various doses of CD45 inhibitor. Similar analysis was performed using B cells isolated from *Cd45^−/−^* mice. (**b**) IL-17A expression in CD19^+^ splenic cells from 10 d infected µMT mice that were recipients of adoptively transferred WT (left) or *Cd45^−/−^* B cells (right). (**c**) Number of CD19^+^IL-17A^+^ cells in spleen of UI vs. 10 d infected animals including: WT or µMT mice, or µMT recipients of WT vs. *Cd45^−/−^* B cells. Each symbol denotes a mouse and the line represents the median value in each group. (**d**) *In vitro* IL-17A secretion by B220^+^CD19^+^ cells derived from WT vs. *Gal-1^−/−^Gal-3^−/−^* mice in response to Tryp-stimulation. (**e**) IL-17A production by WT FM B cells stimulated with Tryp and treated with different concentration of Src inhibitor (PP2) vs. DMSO control. (f) IL-17A production by WT FM B cells stimulated with Tryp and treated with increasing doses of Btk-specific inhibitors (AVL-292 or CNX-652) vs. DMSO control. IL-17A production by Tryp stimulated FO B cells derived from *Btk^−/−^* and *Btk^−/−^Tec^−/−^* mice is also shown. (**g**) Representative FACS plots (left panels) and total number of splenic CD19^+^IL-17A^+^ cells (right panel) in *T. cruzi* infected (10 d) WT or *Btk^−/−^* mice. (h) IL17A production in Tryp stimulated purified B cells derived from BALB/c (control) vs. *Pkcβ^−/−^* mice. All *in vitro* analyses were performed at 72 h and results are representative of three (a--c) or two (d--g) independent experiments for each strain or condition. Data are shown as means ± s.e.m. \*, P ≤ 0.05 \*\*, P ≤ 0.005 (calculated by one-way ANOVA with Bonferroni correction (a--f, h) and Mann-Whitney *U*-test (g)).](nihms445334f4){#F4}

![RORγt and AHR are not required for B cell IL-17 production in response to *T. cruzi*\
(**a**) IL-17 secretion by WT and *Rorγt^−/−^* splenic B cells cultured *in vitro* for 72 hr with *T. cruzi* Tryp, with or without Tsial-neutralizing mAb (α-Tsial) (4 replicates per condition). (**b**) IL-17A production in non-stimulated and Tryp-stimulated, WT B cells (in presence or absence of the RORγt and RORα inhibitor SR1001, 25µM) and *Ahr^−/−^* B cells. Data are shown as means ± s.e.m. \*, P ≤ 0.05 \*\*, P ≤ 0.005 (calculated by one-way ANOVA with Bonferroni correction). (**c**) Number of splenic B220^+^IL-17A^+^ cells in *T. cruzi* infected (10 d) WT, *Rorγt^−/−^* and *Ahr^−/−^* mice. Each symbol denotes a mouse and the line represents the median value in each group. (**d**) *Rorγt* locus activation cannot be detected *in vivo* in B cells following *T. cruzi* infection. RORγt-cre × ROSA-RFP reporter mice were infected with *T. cruzi* and spleens collected at 10 d post-infection. ROSA-RFP (magenta) and IgM (cyan) expression in spleen sections from UI (upper panels) vs. 10 d-infected (lower panels) animals. Results are representative of three (a), two (b, c), or one (d) experiment for each strain or condition.](nihms445334f5){#F5}

![Primary human B cells stimulated with *T. cruzi* produce IL-17\
Purified human CD19^+^ tonsillar B cells were cultured for 72 hr in presence of recombinant IL-10 or BAFF and incubated with *T. cruzi* Tryp with or without α-Tsial mAb. B cells were also treated with Btk (AVL-292) or CD45 inhibitors or DMSO control. Production of (**a**) IL-17A or (**b**) IL-17F determined by ELISA. Data (3 replicates per condition) are shown as means ± s.e.m. \*, P ≤ 0.05 \*\*, P ≤ 0.005 (calculated by one-way ANOVA with Bonferroni correction). Results are representative of 3 independent experiments.](nihms445334f6){#F6}
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